Limited evidence is available for relapsed small-cell lung cancer (SCLC). Five hundred eighty consecutive patients with relapsed SCLC treated at our institute were analyzed. Multivariate analysis identified sensitive relapse and amrubicin treatment as independent favorable prognostic factors for survival. Amrubicin showed a favorable trend compared with cisplatin/etoposide/irinotecan in terms of the progression-free survival and feasibility in SCLC patients with relapsed disease. Background: Although several agents have been introduced for the treatment of relapsed small-cell lung cancer (SCLC), there is still only limited evidence regarding second-and later-line chemotherapies for these patients. Patients and Methods: Consecutive patients with relapsed SCLC treated at the National Cancer Center Hospital between 2000 and 2014 were analyzed. Patients' characteristics and treatments to explore factors associated with the survival outcomes were reviewed. Results: A total of 580 patients diagnosed as having SCLC received first-line chemotherapy/chemoradiotherapy, of which 343 (59%) received second-line chemotherapy. Among the 343 patients, 193, 148, and 2 patients were diagnosed sensitive relapse, refractory relapse, and relapse of unknown sensitivity status, respectively. Second-line chemotherapy regimens used were as follows: amrubicin (AMR) in 188 (55%) patients; weekly cisplatin/etoposide/irinotecan (PEI) in 56 (16%) patients; topotecan in 18 (5.2%) patients; others in 81 (24%) patients. In the analysis including all patients, the following outcomes were obtained for the patients treated with AMR and PEI, respectively: objective response rate: 51% and 73%; median progression-free survival: 4.5 and 4.2 months; median overall survival: 10.0 and 10.8 months. Multivariate analysis identified sensitive relapse to first-line treatment (vs. refractory relapse) (P ¼ .007) and AMR as second-line treatment (vs. PEI) (P ¼ .005) as independent favorable prognostic factors for survival. Conclusion: AMR showed a favorable trend compared with PEI in terms of the progression-free survival and feasibility in SCLC patients with relapsed disease. Based on our findings, we suggest that a randomized trial comparing AMR and PEI is warranted.
extensive disease. [5] [6] [7] [8] Despite their relatively good response to chemotherapy and radiotherapy, the majority of patients with SCLC eventually show disease progression. Therefore, second-line therapy is often required, but the prognosis at relapse is still very poor. 9 Response to second-line chemotherapy is reportedly correlated with the response to first-line therapy, the interval between the completion of initial chemotherapy, and the diagnosis of disease progression. 10 Patients who respond to first-line chemotherapy and show a progression-free interval of over 90 days are most often regarded as showing sensitive relapse, as opposed to those showing a progression-free interval of less than 90 days, who are labeled as having refractory relapse.
11-13
The importance of second-line therapy for SCLC was first proven by the pivotal phase III trial comparing best supportive care and topotecan.
14 Up until today, many studies of second-line treatment have been conducted. 12, 13, 15, 16 In patients with sensitive relapse, the reported overall response rate (ORR) is in the range of 22% to 24%, and the reported median overall survival (OS) is in the range of 5 to 9 months 12, 13, 15, 16 ; on the other hand, in those with refractory relapse, the reported ORR is in the range of 6% to 12%, and the reported median OS is in the range of 3 to 5 months. 11, 14, 16, 17 Topotecan is still recognized as the standard choice worldwide for relapsed SCLC, but its survival benefit is limited. Amrubicin (AMR) is a third-generation anthracycline and potent topoisomerase II inhibitor that received approval in Japan in 2002, and whose efficacy as monotherapy has been shown in several phase II trials. [18] [19] [20] [21] [22] These trials showed an ORR in the range of 36% to 53%, and a median OS in the range of 6 to 14 months. However, randomized phase III trials conducted in Western countries have failed to show its superiority over topotecan. 16 Therefore, the use of AMR is limited throughout the world. Recently, the efficacy of a combination regimen consisting of weekly cisplatin plus etoposide plus irinotecan (PEI) has been demonstrated in patients with relapsed SCLC. In a randomized controlled trial, the median OS was 18.2 months and the ORR was 84%, both superior to those for topotecan. 23 From the many randomized trials conducted for relapsed SCLC, topoisomerase (TOPO) inhibitors appear to be the key drugs for treating SCLC 24 ; however, the choice of the best regimen needs further study.
The objective of the present study was to retrospectively analyze the outcomes of the second-line treatments employed for relapsed SCLC over a 14-year period at our institution. In our analysis, AMR was compared with PEI, because PEI is another choice of secondline regimen alongside topotecan monotherapy after it showed its efficacy in a phase III trial, and no comparison of AMR and PEI has been conducted yet.
Patients and Methods

Data Acquisition
Data of consecutive patients with SCLC receiving chemotherapy at the National Cancer Center Hospital between 2000 and 2014 were analyzed. The patients' clinical characteristics and treatments were collected from the medical records.
Extracted clinical data included the demographic characteristics (gender, age, date of diagnosis, and smoking history), known baseline prognostic factors (Eastern Cooperative Oncology Group performance status [PS] , stage), first-and second-line treatment details (regimen, start, and last day of administration), and clinical outcomes (response to treatment documented by each physician, date of relapse, and date of last follow-up or death). Patients who showed disease progression or relapsed within 90 days of completion of the first-line treatment were classified as having refractory relapse, whereas the remainder were classified as having sensitive relapse.
AMR This retrospective study was conducted with the approval of the Ethics Committee of the National Cancer Hospital (#2014-178), and in accordance with the Declaration of Helsinki.
Statistical Analysis
Response rate was measured by each attending physician based on radiographic images or clinical symptoms using the Response Evaluation Criteria In Solid Tumors (RECIST) guideline (version depending on the year of treatment). 25 
Results
Patient Characteristics and Treatment Outcomes
Between 2000 and 2014, 580 patients with SCLC received firstline chemotherapy or chemoradiotherapy. Among the 512 patients that developed relapse, 343 (59%) received second-line chemotherapy. Of the patients administered receiving second-line chemotherapy, 193 (56%) were diagnosed as having sensitive relapse and 148 (43%) as having refractory relapse. The selection of chemotherapy was left to the discretion of the attending physician. AMR was used most frequently in both groups, followed by PEI, and then irinotecan monotherapy. Of the patients, 31% received third-line treatment, and 11% received fourth-or later lines of treatment. Figure 1 shows the patient flow chart. The baseline characteristics of the patients who received AMR and PEI are shown in Table 1 .
The median duration of chemotherapy was 4 cycles and 6 weeks for AMR and PEI, respectively. The objective response rates (ORR) were 51% and 73%, respectively ( Table 2 ). The median PFS was 
Prognostic Factor Analysis
Multivariate Cox regression analysis of the data from all 244 patients administered second-line AMR or PEI identified sensitivity to first-line chemotherapy (sensitive relapse over refractory relapse) and second-line chemotherapy regimen used (AMR over PEI) as independent predictors of the PFS (Table 3 ). The same analysis revealed sensitivity to first-line chemotherapy (sensitive relapse over refractory relapse) and age (younger than 66 years over 66 years and older) as additional significant factors. We conducted the same analysis after dividing the patients into sensitive-and refractory relapse groups. Of the 128 patients of the sensitive relapse group that received second-line AMR or PEI, PS (0-1 over 2-3) and second-line chemotherapy (AMR over PEI) were identified as independent predictors of the PFS following first-line treatment (See Supplemental Table 1 in the online version). No significant predictive factor for OS was identified. On the other hand, in the 116 patients of refractory relapse treated with AMR or PEI, no significant prognostic factors were identified, although second-line treatment (See Supplemental Table 2 in the online version) was associated with a HR of 1.48 (95% CI, 0.84-2.62) favoring AMR.
Discussion
In a large cohort of SCLC patients treated for disease relapse, we found that AMR and PEI were the most frequently used second-line therapies. Both treatments yielded survival outcomes worthy of notice, with a more favorable trend in the AMR-treated patients. Multivariate analysis identified second-line treatment with AMR as an independent favorable prognostic factor in terms of the PFS. This tendency was also seen in the patient group with sensitive relapse. Furthermore, in the refractory relapse group as well, a more favorable trend for the PFS was observed in the AMR as compared with the PEI treatment group. The median OS in the AMR treatment group was striking, in that it was substantially longer than that reported from phase III trials conducted abroad, where AMR is not considered as a second-line therapy because it failed to show a survival advantage in a randomized phase III trial, and also showed more toxicity. Second-Line AMR or PEI for Relapsed SCLC
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AMR is the world's first anthracycline anti-cancer agent produced entirely through chemical synthesis 26 ; it was first synthesized with the intent of developing an anti-tumor agent stronger than doxorubicin (DXR). The active metabolite amrubicinol plays an important role in the antitumor effect of this drug, and the major mechanism of action of AMR is the stabilization of a cleavable II) . In studies using human tumor xenografts, AMR was demonstrated to exert a stronger antitumor effect than DXR against breast cancer (xenograft MX-1), small cell lung cancer (xenograft LX-1), and gastric cancer (xenografts SC-6, SC-9, and 4-1ST). In vivo research has demonstrated that AMR causes stronger myelosuppression than DXR, but that, however, recovery from the myelosuppressive effect of AMR is more rapid than that from the myelosuppressive effect of DXR. 27 Cardiotoxicity is rarely encountered as compared with that for other anthracycline agents, and cumulative toxicities, such as renal failure associated with platinum agents, is not a concern. Therefore, AMR is a more feasible treatment option, in that it exerts less toxicity and requires fewer days of hospitalization. These findings suggest that AMR is a treatment that can be used for a long time without any substantive concern about cumulative toxicities, as compared with combination therapies based on platinum agents; therefore, AMR is one of the useful drugs that should be considered in the course of treatment in patients with SCLC. Patients with SCLC with sensitive relapse showed a better sensitivity to second-line treatment and a better prognosis as compared with those with refractory relapse. The ORR of 55% and median PFS of 5.3 months in the sensitive relapse group treated with AMR in the present study are similar to the outcomes reported from a phase II trial of an ORR of 67%, median PFS of 5.4 months, and median OS of 14.4 months in patients with SCLC with sensitive relapse assigned to the AMR treatment arm. 28 In the phase III Amrubicin Clinical Trial-1 (ACT-1) trial, the ORR was 40.9%, the median PFS was 5.5 months, and the median OS was 9.2 months in the sensitive relapse subgroup of patients with SCLC treated with AMR. 16 In the patients with SCLC with sensitive relapse treated with PEI in the present study, the ORR was 87% and the median PFS was 4.9 months. According to another randomized phase III trial of PEI in the secondline setting for patients with SCLC with sensitive relapse, the ORR was 84%, the median PFS was 5.7 months, and the median OS was 18.2 months. 23 Interestingly, among the patients with sensitive relapse in the present study, a better survival was obtained in Overall Survival (probability) Second-Line AMR or PEI for Relapsed SCLC the AMR treatment group as compared with the PEI treatment group. With the present data and the historical trial of PEI showing a survival benefit over topotecan, we believe that the true benefit of AMR will become manifest in properly selected patients, for example, those with sensitive relapse. From the aspect of toxicity, there was 1 treatment-related death (1.8%) in the PEI treatment group and 2 treatment-related deaths (1.0%) in the AMR treatment group in this study. Historical data showed a higher adverse event occurrence rate in the PEI treatment group; the grade 3 to 4 adverse events in the PEI treatment group were neutropenia (83.3%), anemia (84.4%), thrombocytopenia (41.1%), diarrhea (7.8%), and febrile neutropenia (FN; 31.1%) . 23 On the other hand, the grade 3 to 4 adverse events in the AMR treatment group were neutropenia (41%), thrombocytopenia (21%), anemia (16%), infections (16%), febrile neutropenia (10%), and cardiac disorders (5%). 16 Myelosuppression is critical, because refractory patients already have depressed bone marrow function. The 3-drug combination of PEI was originally designed as a weekly regimen to make it easier to modify the dosage and schedule. 29, 30 However, the frequency of febrile neutropenia of 31.1% despite granulocyte colony-stimulating factor support is high for patients receiving second-line treatment and is 2-to 3-fold higher as compared with that reported for monotherapy regimens. Furthermore, patients scheduled to receive PEI treatment need to be hospitalized, whereas AMR treatment can be administered on an outpatient basis. Therefore, AMR monotherapy is more feasible and is also associated with lower toxicity. The results also revealed exceptionally long-term survivors in the AMR treatment group. One of these patients received 27 cycles of treatment, and 6 received 16 to 18 cycles. Based on a study of longterm survival in 1714 consecutive SCLC patients, Lassen et al reported a 5-year survival rate of 3.5% 31 ; they reported ED, PS > 2, presence of liver and/or bone marrow metastases, and elevated lactate dehydrogenase and/or alkaline phosphatase levels as negative prognostic factors. In our patient cohort, 6 patients (2.5%) survived for longer than 5 years, and indeed, all 6 patients had limited disease and a PS of 0 to 1. In addition, 5 of the patients received AMR as the second-line treatment, with 3 patients still, at the time of writing, under AMR treatment. AMR is a drug that could be administered over the long term, provided it shows efficacy, as it has very low toxicity. Some of the limitations of this study were that the database was from a single institute, and the study was retrospective in nature; the number of patients in the PEI arm was small; treatment was selected according to the physicians' discretion and may have, therefore, been biased. Also, both treatment groups include patients treated in practice and those enrolled in an ongoing clinical trial at the time. Therefore, some patients' tumor response evaluations were made by the treating physician, whereas others were evaluated according to each trial protocol, which may have contributed to the longer PFS compared with a cohort from a pure clinical trial. Furthermore, our results showed substantially longer median overall survival times as compared with reports from previous phase III trials of AMR or topotecan carried out abroad, which could be related to possible differences in the genetic background, medical care, study design, and/or drug exposure, 32 and the higher frequency of use of post-relapse treatments including AMR, irinotecan, and topotecan in Japan. The similar median overall survival between AMR and PEI in our analysis may possibly have been due to post-relapse treatment or other factors; nonetheless, the long survival and simplicity of the regimen compared with PEI should be valued.
Conclusion
Our results revealed that relapsed patients with SCLC receiving AMR as second-line therapy showed a longer median PFS as compared to those receiving PEI, with a similar median OS between the 2 treatment groups. A longer median PFS with AMR was also confirmed in patients diagnosed as having sensitive relapse. The 2 treatment groups showed different feasibility profiles. AMR is a highly active and well-tolerated treatment option that deserves to be recognized as a second-line treatment of choice as compared with topotecan and PEI, on the basis of the better survival and shorter hospitalization, respectively. Further investigation comparing AMR and PEI in selected patient groups is necessary.
Clinical Practice Points
Despite their relatively good response to chemotherapy and radiotherapy, the majority of patients with SCLC eventually show disease progression. The importance of second-line therapy for SCLC was first proven by the pivotal phase III trial comparing best supportive care and topotecan. Later, many studies of second-line treatment have been conducted, including AMR monotherapy and a combination regimen consisting of PEI. Both regimens have shown a survival benefit over topotecan in randomized trials in Japan. However, AMR failed to show its superiority over topotecan in a phase III trial; therefore, it is not a widely used drug around the world. The choice of the best regimen needs further study. No study has investigated the efficacy comparing AMR and PEI. In our analysis, AMR and PEI were the most used regiments at our institute. The following outcomes were obtained for AMR and PEI, respectively: ORR: 51% and 73%; median PFS: 4.5 and 4.2 months; and median OS: 10.0 and 10.8 months. Multivariate analysis identified sensitive relapse to first-line treatment (vs. refractory relapse) (P ¼ .007) and AMR as second-line treatment (vs. PEI) (P ¼ .005) as independent favorable prognostic factors for survival. AMR showed a more favorable outcome in terms of the feasibility and survival. Exceptionally long-term survivors were observed in patients treated with AMR. Based on our findings, we suggest that a randomized trial comparing AMR and PEI is warranted. 
